Development
Bristol-Myers Squibb Company
BMY
$48.44
$0.631.32%
NYSE
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
P/E (TTM)
--
EPS (TTM)
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 1.76B | 1.93B | 2.07B | 2.26B | 2.02B |
| Total Depreciation and Amortization | 2.42B | 2.45B | 2.45B | 2.45B | 2.45B |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -786.00M | 81.00M | -937.00M | -378.00M | -706.00M |
| Change in Net Operating Assets | 855.00M | 291.00M | -1.70B | -1.36B | -458.00M |
| Cash from Operations | 4.25B | 4.75B | 1.89B | 2.97B | 3.31B |
| Capital Expenditure | -330.00M | -342.00M | -259.00M | -278.00M | -346.00M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -581.00M | -326.00M | -184.00M | -78.00M | -116.00M |
| Divestitures | 241.00M | 247.00M | 194.00M | 227.00M | 711.00M |
| Other Investing Activities | -676.00M | 11.00M | -80.00M | -81.00M | 964.00M |
| Cash from Investing | -1.35B | -410.00M | -329.00M | -210.00M | 1.21B |
| Total Debt Issued | 4.22B | -10.00M | 115.00M | 128.00M | 136.00M |
| Total Debt Repaid | -2.12B | 0.00 | -239.00M | -1.64B | 0.00 |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 0.00 | -4.00B | -905.00M | -250.00M | -2.42B |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -1.16B | -1.19B | -1.20B | -1.20B | -1.15B |
| Other Financing Activities | 25.00M | 41.00M | 53.00M | -92.00M | 179.00M |
| Cash from Financing | 967.00M | -5.16B | -2.17B | -3.05B | -3.25B |
| Foreign Exchange rate Adjustments | 78.00M | -38.00M | -8.00M | 13.00M | 95.00M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3.95B | -857.00M | -623.00M | -277.00M | 1.37B |